" /> Istiratumab - CISMeF





Preferred Label : Istiratumab;

NCIt definition : A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.;

UNII : XLR461MD3M;

CAS number : 1509928-04-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1509928-04-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : MM-141; MM-005;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
05/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.